1-(4-aminobenzoyl)-2-benzalhydrazine | 82973-12-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-aminobenzoyl)-2-benzalhydrazine
• 英文别名: (E)-4-amino-N'-benzylidenebenzohydrazide；4-amino-benzoic acid benzylidenehydrazide；4-Amino-benzoesaeure-benzylidenhydrazid；4-Amino-benzoesaeure-benzalhydrazid；Benzaldehyd-(4-amino-benzoylhydrazon)；4-amino-N-[(E)-benzylideneamino]benzamide
• CAS: 82973-12-4
• 化学式: C₁₄H₁₃N₃O
• 分子量: 239.277
• InChiKey: SIIYIFFQXBUHDX-MHWRWJLKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4-aminobenzoyl)-2-benzalhydrazine 生成 4-[(1H-benzimidazol-2-ylmethyl)-amino]-benzoyl azide
  参考文献：
  名称：

  吐根糖浆中吐根生物碱头孢烯和依米丁在大鼠体内的生物转化。

  摘要：

  在大鼠中研究了吐根糖浆的主要活性成分头孢喹啉和依米丁的代谢。Cephaeline-6'-O-glucuronide 被发现是 cephaeline 的胆汁代谢物。观察到 Cephaeline (6'-O-demethylemetine) 和 9-O-demethylemetine 是 emetine 的酶水解胆汁代谢物。Cephaeline 与葡糖苷酸结合，而 emetine 去甲基化为 cephaeline 和 9-0-demethylemetine，之后可能与葡糖苷酸结合。在给予含有氚 (3H) 的吐根糖浆后 48 小时内，从大鼠身上收集尿液、粪便和胆汁——标记的头孢烯或依米丁。通过薄层色谱法 (TLC) 或高效液相色谱法 (HPLC) 分离和量化代谢物。3H-头孢烯的胆汁和尿排泄率为 57。分别为剂量的 5% 和 16.5%。Cephaeline-6'-O-glucuronide 占胆道放射性的

  DOI：

  10.1007/bf03190402
• 作为产物：
  描述：

  4-氨基苯甲酸甲酯 在 一水合肼 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 10.0h， 生成 1-(4-aminobenzoyl)-2-benzalhydrazine
  参考文献：
  名称：

  阴离子转运蛋白中的腙：第二个结合位点的不利影响

  摘要：

  可以使用能够结合阴离子并将其稳定在双层膜的亲脂内部的阴离子受体来开发合成的阴离子转运蛋白，它们通常包含带有酸性 NH 的官能团，例如脲、硫脲和方酰胺。为了评估酰基腙作为制备阴离子转运蛋白的新官能团的适用性，我们研究了用这些和相关官能团官能化的硫脲家族。1H NMR滴定和DFT计算表明，带有酰基腙基团的硫脲表现为具有两个独立结合位点的氯受体，其中酰基腙的结合比硫脲弱。氯化物转运研究表明，额外的结合位点对基于硫脲的转运蛋白具有不利影响，对于具有两个独立结合位点的双（硫）脲也观察到这种现象。我们提出第二个阴离子结合单元的存在会阻碍硫脲的转运活性，因为它与膜的磷脂有额外的相互作用。与这一假设一致，广泛的分子动力学模拟表明分子将倾向于定位在水/脂质界面中，由硫脲的NH和酰基腙基团与POPC极性头基和水分子的相互作用驱动。此外，相互作用能表明，最差的转运蛋白确实与膜磷脂有最强的相互作用，抑制了氯离子的

  DOI：

  10.1039/d1ob01279g

文献信息

• [EN] GLUCOSE-SENSITIVE PEPTIDE HORMONES<br/>[FR] HORMONES PEPTIDIQUES SENSIBLES AU GLUCOSE
  申请人：GUBRA APS

  公开号：WO2018115462A1

  公开（公告）日：2018-06-28

  The present invention relates to a conjugate of the formula P-L-I, wherein P is a peptide hormone effecting the metabolism of carbohydrates in vivo, L is a hydrolysable linker molecule consisting of Lp and Li, and I is a molecule capable of inhibiting the effect of the peptide hormone P on the metabolism of carbohydrates in vivo. Under in vivo conditions, the conjugate is the major compound. When the concentration of glucose increases in vivo, the concentration of the peptide hormone effecting the metabolism of carbohydrates in vivo also increases.

  本发明涉及一种公式为P-L-I的结合物，其中P是一种肽激素，在体内影响碳水化合物代谢，L是由Lp和Li组成的可水解连接分子，I是一种能够抑制肽激素P对体内碳水化合物代谢影响的分子。在体内条件下，该结合物是主要化合物。当体内葡萄糖浓度增加时，影响碳水化合物代谢的肽激素浓度也会增加。
• SELECTIVE ANTI-MYCOBACTERIAL PREPARATIONS, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS
  申请人：Institut Organicheskogo Sinteza Uralskogo Otdeleniya Rossiiskoi Akademii Nauck

  公开号：EP1081131A1

  公开（公告）日：2001-03-07

  The present invention relates to new non-cyclic analogues of crown ethers (podands). principally di(formylaryl)polyethers, as well as to their hydrazones comprising substituted hydrazines of formula (I) where Ar is substituted phenylen or naphtylen. Y is an atom of hydrogen, halogen or a metoxy group, R is an oxygen atom or a NNH-R1 group, R1 is substituted phenyl, benzoyl or a 2- or 4-nicotinoyl. n is an integer between 1 and 3 and m is an integer between 1 and 4. This invention also relates to pharmaceutically acceptable addition salts and co-ordination compounds used as selective anti-mycobacterial preparations, as well as to a method for producing the same and to pharmaceutical compositions. The compounds of the present invention can essentially be used as an active basis in pharmaceutical preparations used for treating patients affected by mycobactenoses, including tuberculosis. These compounds consist of anti-mycobacterial preparations having a high specificity towards mycobacteria, a high activity against atypical, typical and resistant attains of mycobacteria, as well as a low toxicity. These compounds can be used in practical medicine for treating patients infected by sensitive and resistant as well as by typical and atypical strains of mycobacteria.

  本发明涉及新的冠醚（podands）非环类似物，主要是二（甲酰基芳基）聚醚，以及由式（I）取代的肼组成的肼 其中Ar是取代的苯基或萘基，Y是氢、卤素或甲氧基原子，R是氧原子或NNH-R1基团，R1是取代的苯基、苯甲酰基或2-或4-烟酸基。Y 是氢、卤素或甲氧基原子，R 是氧原子或 NNH-R1 基团，R1 是取代的苯基、苯甲酰基或 2-或 4-烟酰基，n 是介于 1 和 3 之间的整数，m 是介于 1 和 4 之间的整数。本发明还涉及用作选择性抗霉菌制剂的药学上可接受的加成盐和配位化合物，以及生产这些化合物和药物组合物的方法。本发明的化合物基本上可作为药物制剂的活性基础，用于治疗受霉菌病（包括结核病）影响的患者。这些化合物包括对分枝杆菌具有高度特异性的抗分枝杆菌制剂，对非典型、典型和耐药性分枝杆菌具有高活性以及低毒性。这些化合物可用于治疗受敏感和耐药以及典型和非典型分枝杆菌感染的病人。
• Patel; dave; Langalia, Journal of the Indian Chemical Society, 1984, vol. 61, # 8, p. 718 - 720
  作者：Patel、dave、Langalia、Thaker

  DOI：——

  日期：——
• PATEL, J. M.;DAVE, M. P.;LANGALIA, N. A.;THAKER, K. A., J. INDIAN CHEM. SOC., 1984, 61, N 8, 718-720
  作者：PATEL, J. M.、DAVE, M. P.、LANGALIA, N. A.、THAKER, K. A.

  DOI：——

  日期：——
• Synthesis and antimycobacterial activity of some coupling products from 4-aminobenzoic acid hydrazones
  作者：Ş.Güniz Küçükgüzel、Sevim Rollas、Ilkay Küçükgüzel、Muammer Kiraz

  DOI：10.1016/s0223-5234(99)00129-4

  日期：1999.12

  Various 2,3,4-pentanetrione-3- [4-[[(5 -nitro-2-furyl/pyridyl/substituted phenyl)methylene]hydrazinocarbonyl]phenyl] hydrazones 3a-j were synthesized by the reactions of acetylacetone with the diazonium salts of 4-aminobenzoic acid-[(5-nitro-2-furyl/pyridyl/substituted phenyl)methylene]hydrazides 2a-j at 0-5 degrees C. The structures of these compounds were determined using spectral data. All the synthesized compounds were evaluated for their antimycobacterial activity against Mycobacterium fortuitum ATCC 6841 and Mycobacterium tuberculosis H37Rv. Of the compounds screened, 2e, 2i, 3e and 3g were found to be active against M fortuitum at an MIC value of 32 mu g/mL. Compound 3a, which exhibited > 90% inhibition in the primary screen at 12.5 mu g/mL against M tuberculosis H37Rv, was the most promising derivative for antituberculosis activity. Results obtained from the level II screening showed that the actual MIC and IC50 values of 3a were 3.13 and 0.32 mu g/mL, respectively. The same compound was also tested against Mycobacterium avium, which was observed not to be susceptible to 3a. (C) 1999 Editions scientifiques et medicales Elsevier SAS.